{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:32:10Z","timestamp":1793079130633,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.yebeh.2026.111326","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:37:08Z","timestamp":1790890628000},"page":"111326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cognitive Outcomes During Adjunctive Cenobamate Treatment in Patients with Drug-Resistant Epilepsy: An Interim Analysis of a Prospective Observational Study"],"prefix":"10.1016","volume":"185","author":[{"given":"Hanna","family":"Ljung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrea","family":"Frid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6286-554X","authenticated-orcid":false,"given":"Arne","family":"Reimers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Blomgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8349-2044","authenticated-orcid":false,"given":"Maria Compagno","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2026.111326_b0005","doi-asserted-by":"crossref","DOI":"10.1002\/epi4.70298","article-title":"Real-world effectiveness of cenobamate in drug-resistant and ultra-refractory epilepsy: a multicenter study","author":"Str\u00fd\u010dek","year":"2026","journal-title":"Epilepsia Open"},{"issue":"4","key":"10.1016\/j.yebeh.2026.111326_b0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11065-007-9043-9","article-title":"Neuropsychological and behavioral effects of antiepilepsy drugs","volume":"17","author":"Loring","year":"2007","journal-title":"Neuropsychol Rev"},{"issue":"11","key":"10.1016\/j.yebeh.2026.111326_b0015","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.euroneuro.2015.07.027","article-title":"Adverse cognitive effects of antiepileptic pharmacotherapy: each additional drug matters","volume":"25","author":"Witt","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/j.yebeh.2026.111326_b0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1756285611417920","article-title":"The cognitive impact of antiepileptic drugs","volume":"4","author":"Eddy","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111326_b0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.yebeh.2013.07.013","article-title":"Which drug-induced side effects would be tolerated in the prospect of seizure control?","volume":"29","author":"Witt","year":"2013","journal-title":"Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.yebeh.2026.111326_b0030","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.16576","article-title":"Changes in cognition after introduction or withdrawal of zonisamide versus topiramate in epilepsy patients: a retrospective study using Bayes statistics","volume":"61","author":"Meschede","year":"2020","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111326_b0035","first-page":"1","article-title":"Cognitive effects of GABAergic antiepileptic drugs","volume":"60","author":"Czubak","year":"2010","journal-title":"Arzneimittelforschung"},{"issue":"6","key":"10.1016\/j.yebeh.2026.111326_b0040","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/14656566.2017.1309025","article-title":"How can we overcome neuropsychological adverse effects of antiepileptic drugs?","volume":"18","author":"Witt","year":"2017","journal-title":"Exp Opin Pharmacother"},{"issue":"221","key":"10.1016\/j.yebeh.2026.111326_b0045","article-title":"Cognitive and behavioral effects of the anti-epileptic drug cenobamate (YKP3089) and underlying synaptic and cellular mechanisms","volume":"15","author":"Song","year":"2022","journal-title":"Neuropharmacology"},{"issue":"879","key":"10.1016\/j.yebeh.2026.111326_b0050","article-title":"Positive allosteric modulation of GABAAreceptors by a novel antiepileptic drug cenobamate","volume":"15","author":"Sharma","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/j.yebeh.2026.111326_b0055","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","article-title":"Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability","volume":"35","author":"Roberti","year":"2021","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.yebeh.2026.111326_b0060","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s13318-020-00615-7","article-title":"Mass balance, metabolism, and excretion of cenobamate, a new antiepileptic drug, after a single oral administration in healthy male subjects","volume":"45","author":"Vernillet","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"14","key":"10.1016\/j.yebeh.2026.111326_b0065","article-title":"Cenobamate as add-on therapy for drug resistant epilepsies: effectiveness, drug to drug interactions and neuropsychological impact. What have we learned from real word evidence?","volume":"21","author":"Pietrafusa","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.yebeh.2026.111326_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109605","article-title":"Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies","volume":"151","author":"Krauss","year":"2024","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2026.111326_b0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.seizure.2022.10.004","article-title":"Effects of cenobamate on cognitive performance of epilepsy patients","volume":"102","author":"Schuetz","year":"2022","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111326_b0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/epi4.12857","article-title":"Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy","volume":"9","author":"Catal\u00e1n-Aguilar","year":"2024","journal-title":"Epilepsia Open"},{"issue":"2","key":"10.1016\/j.yebeh.2026.111326_b0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40263-024-01063-6","article-title":"Effect of cenobamate on cognition in patients with drug-resistant epilepsy with focal onset seizures: an exploratory study","volume":"38","author":"Serrano-Castro","year":"2024","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111326_b0090","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/13554794.2024.2366472","article-title":"Severe memory decline along with unaffected executive functions under 400 mg\/day of cenobamate leading to a collapse in school performance","volume":"30","author":"Witt","year":"2024","journal-title":"Neurocase"},{"issue":"9","key":"10.1016\/j.yebeh.2026.111326_b0095","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40263-025-01196-2","article-title":"The effects of cenobamate and its dosage on cognition: a retrospective longitudinal study in 84 individuals with epilepsy","volume":"39","author":"Witt","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2026.111326_b0100","series-title":"Memory a compendium of neuropsychological tests: administration, norms, and commentary","first-page":"678","author":"Strauss","year":"2006"},{"key":"10.1016\/j.yebeh.2026.111326_b0105","unstructured":"Claeson L, Esbj\u00f6rnsson E, T\u00e4nn\u00e9rus B, et al. Beskrivning av testet. Claeson-Dahls test f\u00f6r innl\u00e4rning och minne. Reviderad version, Psykologif\u00f6rlaget AB; 1998:39\u201343."},{"key":"10.1016\/j.yebeh.2026.111326_b0110","series-title":"Wechsler Adult Intelligence Scale \u2013 Fourth Edition (WAIS\u2013IV) technical and interpretive manual","author":"Wechsler","year":"2008"},{"key":"10.1016\/j.yebeh.2026.111326_b0115","series-title":"The Delis\u2013Kaplan executive function system: examiner\u2019s manual","author":"Delis","year":"2001"},{"key":"10.1016\/j.yebeh.2026.111326_b0120","series-title":"Trail making test: manual for administration and scoring","author":"Reitan","year":"1992"},{"issue":"6","key":"10.1016\/j.yebeh.2026.111326_b0125","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.yebeh.2026.111326_b0130","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.yebeh.2016.03.003","article-title":"Validation of the hospital anxiety and depression scale in patients with epilepsy","volume":"58","author":"Wiglusz","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111326_b0135","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.acn.2004.08.002","article-title":"A comparison of methods for measuring cognitive change in older adults","volume":"20","author":"Frerichs","year":"2005","journal-title":"Arch Clin Neuropsychol"},{"issue":"6","key":"10.1016\/j.yebeh.2026.111326_b0140","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1097\/HCR.0000000000000379","article-title":"Establishing the minimal clinically important difference for the hospital anxiety and depression scale in patients with cardiovascular disease","volume":"39","author":"Lemay","year":"2019","journal-title":"J Cardiopulm Rehabil Prev"},{"issue":"10","key":"10.1016\/j.yebeh.2026.111326_b0145","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.3390\/jcm13102757","article-title":"Cenobamate plasma levels in patients with epilepsy: correlation with efficacy and tolerability?","volume":"13","author":"Steinhoff","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.yebeh.2026.111326_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2025.110838","article-title":"Psychiatric effects of cenobamate in adults with epilepsy: a retrospective study","volume":"175","author":"Ferlisi","year":"2026","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505026004476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505026004476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:33:38Z","timestamp":1793075618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505026004476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":30,"alternative-id":["S1525505026004476"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.111326","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognitive Outcomes During Adjunctive Cenobamate Treatment in Patients with Drug-Resistant Epilepsy: An Interim Analysis of a Prospective Observational Study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.111326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111326"}}